

Commercial/Healthcare Exchange PA Criteria

Effective: May 1, 2018

Prior Authorization: Bowel Preparations

Products Affected: Prepopik, Clenpiq, Plenvu

Medication Description: Clenpiq (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution is a stimulant and osmotic laxative that is provided as a cranberry-flavored, colorless to slightly yellow, clear oral solution, and is supplied as two bottles in each carton. Each bottle of Clenpiq contains 10 mg sodium picosulfate, USP; 3.5 g magnesium oxide, USP; and 12 g anhydrous citric acid, USP. The product also contains the following inactive ingredients: acesulfame potassium, cranberry flavor, disodium edetate, malic acid, sodium benzoate, sodium hydroxide, sodium metabisulfite, sucralose, and water. The cranberry flavor contains glyceryl triacetate (triacetin), maltodextrin and sodium octenyl succinated starch.

Covered Uses: Cleansing of the colon as a preparation for colonoscopy.

Exclusion Criteria:

1. Patients with severely reduced renal function (creatinine clearance less than 30 mL/minute) [**Clenpiq/Prepopik**]
2. Bowel perforation
3. Gastric retention
4. Gastrointestinal obstruction or ileus
5. Toxic colitis or toxic megacolon

Required Medical Information:

1. Previous therapy tried/failed
2. Chart notes documenting treatment failure or allergy

Age Restrictions:

Clenpiq, Prepopik: 9 years of age and older

Plenvu: 18 years of age and older

Prescriber Restrictions: Prescribed by or in consultation with a gastroenterologist.

Coverage Duration: 12 months

Other Criteria:

- A. Member has history of failure of Suprep OR MoviPrep defined as:
 - a. Failure to complete cleansing of the colon as a preparation for colonoscopy; OR
- B. Member has intolerance to Suprep OR MoviPrep, defined as (but not limited to):
 - a. Allergic reaction; OR
 - b. Adverse drug reactions

References:

1. Clenpiq [package insert]. Parsippany, NJ; Ferring Pharmaceuticals; October 2019.
2. Prepopik [package insert]. Parsippany, NJ; Ferring Pharmaceuticals; August 2018.

3. “Task Force Releases Updated Recommendations for Colorectal Cancer Screening.” American Gastroenterological Association. June 22, 2017. www.gastro.org/news_items/task-force-releases-updated-recommendations-for-colorectal-cancer-screening. Accessed February 28, 2018.
4. “Colonoscopy.” National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Department of Health and Human Services. July 2017. www.niddk.nih.gov/health-information/diagnostic-tests/colonoscopy. Accessed February 28, 2018.
5. PLENVU(R) powder for oral solution, polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, potassium chloride powder for oral solution. Salix Pharmaceuticals Ltd (per FDA), Bridgewater, NJ, May 2019.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	04/17/2018
2	Update	Addition of new drug: Plenvu	Products Affected	08/28/2018
3	Update	Age Restriction for Prepopik	Age Restriction	5/2019
4	Update	Updates per FDA label	Exclusion Criteria Age Restrictions	01/14/2020